Monica L Guzman1, Craig T Jordan. 1. Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology/Oncology, University of Kentucky Medical Center, Lexington, Kentucky, USA.
Abstract
BACKGROUND: Malignant stem cells have been identified in acute myelogenous leukemia, chronic myeloid leukemia, and some types of acute lymphoblastic leukemia. Like normal stem cells, these leukemic stem cells (LSCs) are able to self-renew, differentiate, and proliferate extensively. Evidence suggests that LSCs are critical for the initiation and perpetuation of leukemic disease. METHODS: We reviewed the literature describing the characteristic features of LSCs in various leukemias and the novel molecular approaches being used to specifically ablate the LSC population. RESULTS: Studies have demonstrated the potential importance of ablating LSCs when treating leukemia. The unique characteristics of LSCs that differentiate them from their normal counterparts can be exploited to specifically target the malignant population. CONCLUSIONS: Current therapeutic strategies may not effectively ablate the LSC, leaving the potential for disease progression or relapse. A better understanding of LSC cell and molecular biology will allow the design of more effective therapies.
BACKGROUND: Malignant stem cells have been identified in acute myelogenous leukemia, chronic myeloid leukemia, and some types of acute lymphoblastic leukemia. Like normal stem cells, these leukemic stem cells (LSCs) are able to self-renew, differentiate, and proliferate extensively. Evidence suggests that LSCs are critical for the initiation and perpetuation of leukemic disease. METHODS: We reviewed the literature describing the characteristic features of LSCs in various leukemias and the novel molecular approaches being used to specifically ablate the LSC population. RESULTS: Studies have demonstrated the potential importance of ablating LSCs when treating leukemia. The unique characteristics of LSCs that differentiate them from their normal counterparts can be exploited to specifically target the malignant population. CONCLUSIONS: Current therapeutic strategies may not effectively ablate the LSC, leaving the potential for disease progression or relapse. A better understanding of LSC cell and molecular biology will allow the design of more effective therapies.
Authors: Courtney L Jones; Brett M Stevens; Angelo D'Alessandro; Julie A Reisz; Rachel Culp-Hill; Travis Nemkov; Shanshan Pei; Nabilah Khan; Biniam Adane; Haobin Ye; Anna Krug; Dominik Reinhold; Clayton Smith; James DeGregori; Daniel A Pollyea; Craig T Jordan Journal: Cancer Cell Date: 2018-11-12 Impact factor: 31.743
Authors: Jie Lu; Alexander Ksendzovsky; Chunzhang Yang; Gautam U Mehta; Raymund L Yong; Robert J Weil; Deric M Park; Harry M Mushlin; Xueping Fang; Brian M Balgley; Dae-Hee Lee; Cheng S Lee; Russell R Lonser; Zhengping Zhuang Journal: J Neurosurg Date: 2012-10-12 Impact factor: 5.115
Authors: Monica L Guzman; Randall M Rossi; Sundar Neelakantan; Xiaojie Li; Cheryl A Corbett; Duane C Hassane; Michael W Becker; John M Bennett; Edmund Sullivan; Joshua L Lachowicz; Andrew Vaughan; Christopher J Sweeney; William Matthews; Martin Carroll; Jane L Liesveld; Peter A Crooks; Craig T Jordan Journal: Blood Date: 2007-09-05 Impact factor: 22.113
Authors: Jiangbing Zhou; Hao Zhang; Peihua Gu; Jining Bai; Joseph B Margolick; Ying Zhang Journal: Breast Cancer Res Treat Date: 2007-10-27 Impact factor: 4.872
Authors: E Camilla Forsberg; Emmanuelle Passegué; Susan S Prohaska; Amy J Wagers; Martina Koeva; Joshua M Stuart; Irving L Weissman Journal: PLoS One Date: 2010-01-20 Impact factor: 3.240